<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>242184</rcn>
  <id>101090312</id>
  <acronym>OncoNanoR</acronym>
  <teaser>Malignant pleural mesothelioma (MPM) is a highly aggressive disease, where chemotherapy remains the standard of care, enabling an overall survival (OS) of 12 months. Anti-PD-1-based immunotherapy has not improved the patient's OS, while providing only a response rate of 21%...</teaser>
  <objective>Malignant pleural mesothelioma (MPM) is a highly aggressive disease, where chemotherapy remains the standard of care, enabling an overall survival (OS) of 12 months. Anti-PD-1-based immunotherapy has not improved the patient's OS, while providing only a response rate of 21%, owing to the immunosuppressive tumor microenvironment.
The originality of this proposal relies on engineering a novel form of immunotherapy for the treatment of MPM, through activating the innate and adaptive tumor microenvironment, upon one single intravenous injection of self-amplifying RNA, intracellularly delivered by a targeted LipidNanoparticle, which has recently proven to successful target small drugs to orthotopic MPM.
This proposal challenges a major dogma in onconanomedicine  targeting nucleic acids to extra-hepatic tumors - where I will have the guidance of Prof. Moreira from CNC, UC, who holds more than 25 years of experience in the field of targeted delivery to solid tumors, being a successful entrepreneur. Supervision will be complemented with the guidance of an immunologist (APaiva), clinical pathologist (ACarmo), expert on physical-chemistry of colloids (BSilva) and drug development (Srgio Simes, supervisor at Bluepharma Pharmaceutical Industry).
This Marie Sklodowska-Curie European Fellowship, in line with Europe Mission on Cancer, is a life time opportunity to gain a number of different transferable skills, mentoring and leadership, networking and knowledge dissemination, exploitation and communication. These will enable me to become a highly qualified researcher, able to generate and integrate differentiated and interdisciplinary knowledge, and with know-how on how to translate it towards the market and the patients. As such, a wide avenue of opportunities will be open to further pursue a career either in Academia as Principal Investigator/Group Leader or Senior Scientist in the R&amp;D department of a company dedicated to cancer immunotherapies and/or complexes injectables.</objective>
  <title>Engineering the immunosuppressive microenvironment in mesothelioma with targeted LipidNanoParticles encapsulating self-amplifying RNA</title>
  <totalCost>0</totalCost>
  <ecMaxContribution>215773.2</ecMaxContribution>
  <startDate>2023-01-01</startDate>
  <endDate>2025-06-30</endDate>
  <ecSignatureDate>2022-09-19</ecSignatureDate>
  <duration>30</duration>
  <status>CLOSED</status>
  <keywords>Targeting, Lipid NanoParticles, self-amplifying RNA, tumor microenvironment, mesothelioma</keywords>
  <identifiers>
    <grantDoi>10.3030/101090312</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2023-05-20 16:24:48</sourceUpdateDate>
  <contentCreationDate>2022-09-27 17:17:20</contentCreationDate>
  <contentUpdateDate>2025-09-01 23:37:01</contentUpdateDate>
  <lastUpdateDate>2025-09-19 14:49:06</lastUpdateDate>
  <terminationDate>2024-04-23 00:00:00</terminationDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>438481</rcn>
        <id>438481-innovative-immunotherapy-for-the-treatment-of-malignant-pleural-mesothelioma</id>
        <title>Innovative immunotherapy for the treatment of malignant pleural mesothelioma</title>
        <contentUpdateDate>2023-02-27 13:05:12</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode>/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55384</rcn>
        <title>HORIZON-WIDERA-2022-TALENTS-02</title>
        <identifier>HORIZON-WIDERA-2022-TALENTS-02</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55384</rcn>
        <title>HORIZON-WIDERA-2022-TALENTS-02</title>
        <identifier>HORIZON-WIDERA-2022-TALENTS-02</identifier>
      </call>
      <organization netEcContribution="215773.2" totalCost="0" source="corda" order="1" ecContribution="215773.2" terminated="false" sme="false" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>1907348</rcn>
        <id>997826391</id>
        <vatNumber>PT501617582</vatNumber>
        <legalName>UNIVERSIDADE DE COIMBRA</legalName>
        <shortName>UNIVERSIDADE DE COIMBRA</shortName>
        <address>
          <street>PACO DAS ESCOLAS</street>
          <city>Coimbra</city>
          <postalCode>3004-531</postalCode>
          <country>PT</country>
          <postBox>000</postBox>
          <url>http://www.uc.pt</url>
          <geolocation>40.3312438,-8.39288289052555</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/HES</code>
              <title>Higher or Secondary Education Establishments</title>
              <displayCode>/Higher or Secondary Education Establishments</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <rcn>1471666</rcn>
              <nutsCode>PT192</nutsCode>
            </region>
            <region type="relatedRegion">
              <name>Portugal</name>
              <rcn>427199016</rcn>
              <nutsCode>PT</nutsCode>
              <euCode>PT</euCode>
              <isoCode>PT</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <organization netEcContribution="0" totalCost="0" source="corda" order="2" terminated="false" sme="false" type="associatedPartner">
        <availableLanguages>en</availableLanguages>
        <rcn>2394343</rcn>
        <id>952690545</id>
        <vatNumber>PT505282801</vatNumber>
        <legalName>BLUEPHARMA - INDUSTRIA FARMACEUTICASA</legalName>
        <shortName>BLUEPHARMA</shortName>
        <address>
          <street>SAO MARTINHO DO BISPO</street>
          <city>Coimbra</city>
          <postalCode>3045 016</postalCode>
          <country>PT</country>
          <geolocation>40.20904125,-8.46868432806101</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode>/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <rcn>1471666</rcn>
              <nutsCode>PT192</nutsCode>
            </region>
            <region type="relatedRegion">
              <name>Portugal</name>
              <rcn>427199016</rcn>
              <nutsCode>PT</nutsCode>
              <euCode>PT</euCode>
              <isoCode>PT</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>705804</rcn>
        <id>HORIZON.4.1.5</id>
        <code>HORIZON.4.1.5</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.4.1.5</pga>
        <title>Fostering brain circulation of researchers and excellence initiatives</title>
        <parent>
          <programme>
            <rcn>705799</rcn>
            <code>HORIZON.4.1</code>
            <parent>
              <programme>
                <rcn>705798</rcn>
                <code>HORIZON.4</code>
                <parent>
                  <programme>
                    <rcn>705725</rcn>
                    <code>HORIZON</code>
                  </programme>
                </parent>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>706009</rcn>
        <id>HORIZON_HORIZON-WIDERA-2022-TALENTS-02-01</id>
        <code>HORIZON-WIDERA-2022-TALENTS-02-01</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>Fostering balanced brain circulation – ERA Fellowships</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705799</rcn>
        <id>HORIZON.4.1</id>
        <code>HORIZON.4.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.4.1</pga>
        <title>Widening participation and spreading excellence</title>
        <parent>
          <programme>
            <rcn>705798</rcn>
            <code>HORIZON.4</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1124071</rcn>
        <id>101090312_3_DELIVHORIZON</id>
        <title>Communication, Dissemination &amp; Outreach Plan</title>
        <description>"Dissemination plan. I will present the research findings at the CNC (weekly) seminars series (oral communication, one per year) and at the following international conferences: Spanish-Portuguese Local Chapter of the Controlled Release Society – CRS (SPLC-CRS, 2022; oral communication; with 200 participants in 2018); Portuguese Association for Cancer Research (ASPIC, 2023; oral communication; with 700 participants in 2020) and a poster at the Annual Meeting of the American Association for Cancer Research, AACR (2023; with, approximately, 22500 participants in 2019). I will also provide 1 lecture/year at the master course on Pharmaceutical Biotechnology, MPB (Faculty of Pharmacy, UC, FPUC) and at the advanced course on Principles and Practice in Drug Development, PPDD (from CNC PhD program on Biomedicine and Experimental Biology), both averaging 20-30 students and coordinated by the PI. I expect to publish (all in green open-access) 2 original manuscripts (#1 on WPs1&amp;2, at ACS Nano, IF: 15.881; and #2 on WPs3&amp;4, at Nano Today, IF: 20.722), and after patent (PCT) submission. One review article (#3, including experience arising from WPs1-5) is also expected to be published at Trends in Biotechnology (IF: 14.343) on the translational challenges of RNA-containing LNPs for cancer therapy. This plan will impact dissemination among other peers (users), expert researchers (users) and clinicians (end-users), increasing awareness on the need of a targeted treatment for MPM, as well as educational training of, at least, 2 master students (TABLE 1). The 6-month period at Bluepharma will contribute to successfully start bridging the gap with the market.Exploitation plan. Novel intellectual property will be generated on a novel immunotherapy NCL-LNP(saIRF5/IL-12-saRNAs) for the treatment of MPM, properly framed after performing a freedom-to-operate. Good research practices in record keeping and pre-publication reviews will be observed to avoid value leakage and secure IP. I will engage in IP management training (Section 1.3). The patent filling (month 14) will be performed through the Technology Transfer Office (UC Business), with the supervisor involvement (has successfully licensed 5/9 patents). Companies in the field of nucleic acid delivery and/or complex injectables (Pfizer, BioNTech, Moderna, Acuitas, Alnylam or Bluepharma) are potential clients for the new IP. From the company and society perspective, overall (direct) impact is expected upon addressing an unmet medical need in MPM, associated with a novel form of immunotherapy, with replication potential to other nucleolin-overexpressing tumors. A license deal will be negotiatedby UC, based on upfront and milestones payments, plus royalties on annual sales.Communication activities. I will take advantage of CNC/UC’s dedicated Science Communication Office (SCO) with well-established dissemination/communication channels, including media and broad end-users’ (TV, radio, newspapers, blogs and social networks) and engage in relevant communication and outreach activities to raiseawareness about MPM, and contribute to the development of scientific and technological literacy and culture by the public: (1) Design and propose a MPM thematic activity to be presented in the 2022 and 2023 editions of the European Researchers’ Night, organized by CNC in collaboration with the UC-Science Museum and IEC - an institute promoting scientific education and literacy in the rural community of the region (www.educacao-ecidadania.pt); (2) Participate in the “Open Days” and “Science &amp; Technology Week” (open-doors initiatives), welcoming high-school student visits to the Tumor Microenvironment and Targeted Therapies group laboratories; (3) Devise an activity (e.g., leaflet, cartoon, video) targeting MPM risk factors/groups (e.g., asbestos) to be released on the World Cancer Day (4th February) through the appropriate CNC-channels (YouTube, Facebook, institutional webpage (www.cnbc.pt/outreach/"</description>
        <sourceUpdateDate>2024-06-25 18:13:45</sourceUpdateDate>
        <contentUpdateDate>2024-07-01 14:07:00</contentUpdateDate>
        <relations>
          <associations>
            <webLink source="corda" type="projectDeliverable">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <id>5641ace09dc50c8e22838bc91323d868</id>
              <physUrl>https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e50e41fb06&amp;appId=PPGMS</physUrl>
              <defaultLanguage>en</defaultLanguage>
            </webLink>
          </associations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/deliverable</code>
              <title>Project deliverable</title>
              <description>Result: Project deliverables</description>
              <displayCode>/Project deliverable</displayCode>
            </category>
            <category classification="deliverableType" type="isDeliveredAs">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/R</code>
              <title>Documents, reports</title>
              <displayCode>/Documents, reports</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1139613</rcn>
        <id>101090312_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - OncoNanoR (Engineering the immunosuppressive microenvironment in mesothelioma with targeted LipidNanoParticles encapsulating self-amplifying RNA)</title>
        <description>periodic</description>
        <teaser>Malignant pleural mesothelioma (MPM) is a highly aggressive disease and standard chemotherapy treatment achieves an overall survival of 12 months. Anti–programmed cell death 1 protein immunotherapy has a low response rate and does not improve the patient's survival due to...</teaser>
        <sourceUpdateDate>2024-07-28 15:35:29</sourceUpdateDate>
        <contentUpdateDate>2024-08-05 12:21:09</contentUpdateDate>
        <relations>
          <associations>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/101090/101090312_PS/graph-abst-last.jpg</uri>
              <alternativeText>General scheme of the project</alternativeText>
              <mimetype>image/jpeg</mimetype>
              <size>220160</size>
            </webItem>
          </associations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode>/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>998392</rcn>
        <id>101090312_1_DELIVHORIZON</id>
        <title>Data Management Plan</title>
        <description>Once the essential IP rightsinterests have been secured project publications will be available in Green open access and the analogous holds true for the generated materials technologies and overall data following FAIR guidelines UC features its own scientific production repository  Estudo Geral and we will use an online data repository such as Zenodo</description>
        <sourceUpdateDate>2023-11-03 10:07:41</sourceUpdateDate>
        <contentUpdateDate>2023-11-06 15:02:25</contentUpdateDate>
        <relations>
          <associations>
            <webLink source="corda" type="projectDeliverable" represents="project">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <id>bda1d320b8cb6b25b08a98540aba0cae</id>
              <physUrl>https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e502c10ec2&amp;appId=PPGMS</physUrl>
              <defaultLanguage>en</defaultLanguage>
            </webLink>
          </associations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/deliverable</code>
              <title>Project deliverable</title>
              <description>Result: Project deliverables</description>
              <displayCode>/Project deliverable</displayCode>
            </category>
            <category classification="deliverableType" type="isDeliveredAs">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/R</code>
              <title>Documents, reports</title>
              <displayCode>/Documents, reports</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/29/91/523/1309</code>
        <title>entrepreneurship</title>
        <displayCode>/social sciences/economics and business/business and management/entrepreneurship</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/23/43/263/803</code>
        <title>soft matter physics</title>
        <displayCode>/natural sciences/physical sciences/condensed matter physics/soft matter physics</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/23/49/337/1021</code>
        <title>RNA</title>
        <displayCode>/natural sciences/biological sciences/genetics/RNA</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/155/643</code>
        <title>immunotherapy</title>
        <displayCode>/medical and health sciences/basic medicine/immunology/immunotherapy</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-TMA-MSCA-PF-EF</code>
        <title>HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships</title>
        <description>HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships</description>
        <displayCode>/HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>